Friday, November 14, 2014

SciBX: Science-Business eXchange Contents: November 13 2014, Volume 7 / Issue 44

If you are unable to see the message below, click here to view.
SciBX: Science-Business eXchange

You may have received an outdated SciBx etoc yesterday from us which was sent out by mistake. Please find below the current issue's etoc for SciBx. We apologise for any confusion this may have caused.

Advertisement
Biopharma Dealmakers
A supplement to Nature Biotechnology and Nature Reviews Drug Discovery

The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Harbour Antibodies BV.
 

TABLE OF CONTENTS

November 13 2014, Volume 7 / Issue 44

Analysis

Cover Story
Translational Notes
Tools

The Distillery: Therapeutics

Cancer
Cardiovascular disease
Endocrine/metabolic disease
Infectious disease
Musculoskeletal disease
Neurology

The Distillery: Techniques

Computational models
Disease models
Drug delivery
Drug platforms
Instrumentation
Markers
Advertisement
Biopharma Dealmakers
A supplement to Nature Biotechnology and Nature Reviews Drug Discovery

The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Immunovaccine Inc.


 

Analysis

Cover Story

Top

Boosting adjuvants
Stephen Parmley
doi:10.1038/scibx.2014.1281
The NIH is committing $70 million to creating new adjuvants that can work with different types of vaccines and wants industry to get involved.
Full Text | PDF

Translational Notes

Top

Translational tidbits
Kai-Jye Lou, Stephen Parmley and Mark Zipkin
doi:10.1038/scibx.2014.1282
Merck KGaA enters the tankyrase race; Pluristem joins with Case Western to test its new cell therapy; Astellas' AIM unit targets Boston for innovation; the White House clamps down on gain-of-function studies; a round-up of public-private partnerships.
Full Text | PDF

Tools

Top

Building blood vessels
Kai-Jye Lou
doi:10.1038/scibx.2014.1283
Indiana University researchers have found a route to building blood vessels by developing a protocol to generate mass quantities of endothelium-forming cells.
Full Text | PDF

SQZ Biotech's main squeeze
Michael J. Haas
doi:10.1038/scibx.2014.1284
Two awards totaling over $300,000 will fuel SQZ Biotech's scale-up of its microfluidics-based CellSqueeze platform that delivers bioactive materials directly into cells.
Full Text | PDF

Distillery: Therapeutics

Cancer

Top

Bone morphogenetic protein 4 (BMP4); BMP5; smoothened (SMO)
doi:10.1038/scibx.2014.1285
Mouse studies suggest activating BMP4 and BMP5 signaling could help treat bladder cancer.
Full Text | PDF

PDZ binding kinase (PBK; TOPK)
doi:10.1038/scibx.2014.1286
Mouse studies suggest a selective TOPK inhibitor could be used to treat breast and lung cancer.
Full Text | PDF

Epidermal growth factor receptor 3 (EGFR3; HER3; ErbB3)
doi:10.1038/scibx.2014.1287
In vitro studies identified a bivalent, ATP-competitive HER3 antagonist that could help treat HER3-dependent cancers.
Full Text | PDF

Phosphoinositide 3-kinase (PI3K); PI3K class 3 (Vps34)
doi:10.1038/scibx.2014.1288
In vitro studies have identified the small molecule SAR405 as a potent and selective Vps34 inhibitor that could help treat cancer.
Full Text | PDF

Toll-like receptor 4 (TLR4); HPV antigens; survivin (BIRC5)
doi:10.1038/scibx.2014.1289
Mouse studies suggest a combination of adjuvants could help improve the efficacy of cancer vaccines.
Full Text | PDF

Cardiovascular disease

Top

p53
doi:10.1038/scibx.2014.1290
Mouse studies suggest activating p53 in cardiac fibroblasts could help treat ischemia/reperfusion injury.
Full Text | PDF

Endocrine/metabolic disease

Top

Ceramide synthase 6 (CERS6; LASS6)
doi:10.1038/scibx.2014.1291
In vitro and mouse studies suggest inhibiting CERS6 could help treat obesity and diabetes.
Full Text | PDF

Adenosine A2A receptor (ADORA2A)
doi:10.1038/scibx.2014.1292
Mouse studies suggest ADORA2A agonists could activate brown adipose tissue (BAT) to help treat obesity.
Full Text | PDF

Estrogen receptor-α; peroxisome proliferation–activated receptor-γ coactivator 1α (PPARGC1A; PGC-1α)
doi:10.1038/scibx.2014.1293
In vitro and mouse studies suggest increasing hypothalamic PGC-1α expression could help protect against obesity and metabolic disorders.
Full Text | PDF

Infectious disease

Top

Ixodes scapularis antifreeze glycoprotein (iafgp); poly-N-acetyl glucosamine (PNAG)
doi:10.1038/scibx.2014.1294
Rodent, fruit fly and cell culture studies suggest iafgp derived from the I. scapularis tick could help prevent and treat bacterial infections by disrupting biofilm formation.
Full Text | PDF

Cyclophilin
doi:10.1038/scibx.2014.1295
Cell culture studies suggest nonimmunosuppressive cyclosporine-based cyclophilin inhibitors could help treat HCV infections with decreased toxicity risk.
Full Text | PDF

Musculoskeletal disease

Top

Sphingosine 1-phosphate receptor 3 (S1PR3; S1P3; EDG3); calcitonin receptor
doi:10.1038/scibx.2014.1296
Mouse studies suggest antagonizing the calcitonin receptor or agonizing S1PR3 could help treat osteoporosis.
Full Text | PDF

Neurology

Top

Sterol O-aceyltransferase 1 (SOAT1; ACAT1); β-amyloid (Aβ); Aβ42
doi:10.1038/scibx.2014.1297
Cell culture and mouse studies suggest inhibitors of ACAT1 could help treat AD by promoting microglia-mediated clearance of Aβ.
Full Text | PDF

Borna disease virus p10 (BDV p10; BDV X; BDVgp1a)
doi:10.1038/scibx.2014.1298
Mouse and cell culture studies suggest a peptide derived from BDV X could help treat PD.
Full Text | PDF

Distillery: Techniques

Computational models

Top

Somatic mutation finder (SMUFIN) to identify single-nucleotide variants (SNVs) and structural variants in tumor DNA
doi:10.1038/scibx.2014.1299
The SMUFIN computational approach could help identify different forms of somatic mutations in cancer.
Full Text | PDF

Disease models

Top

Clustered, regularly interspaced short palindromic repeats (CRISPR)-Cas9 genome editing for creating mice bearing oncogenic chromosomal arrangements
doi:10.1038/scibx.2014.1300
CRISPR-Cas9 genome editing could be useful for creating mice bearing oncogenic chromosomal arrangements such as EML4-ALK oncogenic fusion protein.
Full Text | PDF

Drug delivery

Top

Protein nanocapsules for tumor-targeted delivery of recombinant p53 protein
doi:10.1038/scibx.2014.1301
Tumor-targeted protein nanocapsules could be useful for delivering anticancer proteins.
Full Text | PDF

Drug platforms

Top

CD8 + T cells that express phosphopeptide-targeted T cell receptor (TCR) to treat cancer
doi:10.1038/scibx.2014.1302
Mouse studies suggest CD8+ T cells expressing TCRs that engage with phosphopeptide antigens could help treat various cancers.
Full Text | PDF

Cell therapy for Parkinson's disease (PD) using dopamine-like neurons differentiated from induced primitive neural stem cells
doi:10.1038/scibx.2014.1303
Rat studies suggest dopamine-like neurons differentiated from neural stem cells could help treat PD.
Full Text | PDF

Human pluripotent stem cell–derived intestinal organoids with in vivo functionality
doi:10.1038/scibx.2014.1304
Mouse studies suggest human intestinal organoids (HIOs) could be used for intestinal regeneration and to study GI infections.
Full Text | PDF

Instrumentation

Top

Microcapillary rheometer for obtaining viscosity measurements of therapeutic protein solutions
doi:10.1038/scibx.2014.1305
A pressure-driven microcapillary rheometer could measure viscosity using small sample volumes, which could help determine the amenability of therapeutic proteins to syringe-mediated delivery.
Full Text | PDF

Markers

Top

Long noncoding RNA (lncRNA) markers for prostate cancer
doi:10.1038/scibx.2014.1306
A panel of lncRNAs could be useful as markers for detecting prostate cancer.
Full Text | PDF

Non–small cell lung cancer (NSCLC) tumor heterogeneity as a predictor of disease outcomes
doi:10.1038/scibx.2014.1307
Genomic sequencing studies suggest NSCLC intratumoral heterogeneity could help predict disease outcome.
Full Text | PDF

Top

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: